MNG705
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.376
- KRAS_SIGNALING_DN+0.322
- HEDGEHOG_SIGNALING+0.321
- TNFA_SIGNALING_VIA_NFKB+0.291
- MYOGENESIS+0.279
- ESTROGEN_RESPONSE_EARLY+0.244
- HYPOXIA+0.244
- PANCREAS_BETA_CELLS+0.241
- APICAL_JUNCTION+0.185
- COAGULATION+0.180
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.542
- PROTEIN_SECRETION-0.493
- INTERFERON_ALPHA_RESPONSE-0.439
- MYC_TARGETS_V1-0.417
- DNA_REPAIR-0.376
- ADIPOGENESIS-0.365
- PI3K_AKT_MTOR_SIGNALING-0.358
- INTERFERON_GAMMA_RESPONSE-0.333
- ALLOGRAFT_REJECTION-0.322
- PEROXISOME-0.298
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613760 | — | E | 0.835 |
| 2 | MNG145 | — | — | 0.808 |
| 3 | SRR4296064 | — | cohortA1 | 0.807 |
| 4 | a2a777ef-9294-4acf-b489-27bc17272b5e | — | — | 0.807 |
| 5 | SRR8613753 | — | C | 0.797 |
| 6 | SRR26320080 | — | — | 0.796 |
| 7 | SRR1083100 | GTEX | — | 0.795 |
| 8 | MNG508 | — | — | 0.793 |
| 9 | BS_97M1E2DW | Diffuse intrinsic pontine glioma | — | 0.788 |
| 10 | SRR6013476 | — | cohortSQ1 | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.376 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.322 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.321 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.291 | Inavolisib | — uncovered |
| MYOGENESIS | 0.279 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.244 | Inavolisib | — uncovered |
| HYPOXIA | 0.244 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.241 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.185 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.171 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.162 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.138 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.108 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.088 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.084 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.079 | Inavolisib | — uncovered |
| APOPTOSIS | 0.034 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.029 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.002 | Inavolisib | — uncovered |